8-KMaterial AgreementsExhibits & Filings

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Material Agreement (Dec 4, 2009)

Filed December 4, 2009For Securities:VRTX

Summary

Vertex Pharmaceuticals Incorporated (VRTX) filed an 8-K on December 4, 2009, to report a material definitive agreement related to a significant equity offering. The company entered into an underwriting agreement on December 2, 2009, to sell 11,500,000 shares of common stock at $38.50 per share. Furthermore, the underwriters exercised their option to purchase an additional 1,500,000 shares, bringing the total shares sold to 13,000,000. This offering represents a substantial capital raise for Vertex Pharmaceuticals, likely intended to fund ongoing research and development, clinical trials, or general corporate purposes. Investors should note the substantial dilution that this significant increase in outstanding shares may entail. The filing details the involvement of major underwriters, including Goldman, Sachs & Co., Merrill Lynch, Pierce, Fenner & Smith Incorporated, J.P. Morgan Securities Inc., and Morgan Stanley & Co. Incorporated, underscoring the breadth and scale of this transaction.

Key Highlights

  • 1Vertex Pharmaceuticals entered into an underwriting agreement on December 2, 2009, to sell 11,500,000 shares of common stock.
  • 2The public offering price for the shares was set at $38.50 per share.
  • 3Underwriters exercised an option to purchase an additional 1,500,000 shares on December 3, 2009.
  • 4The total number of shares sold in the offering amounted to 13,000,000.
  • 5The offering was conducted through a prospectus supplement dated December 2, 2009, and an accompanying prospectus dated September 17, 2008.
  • 6Key underwriters included Goldman, Sachs & Co., Merrill Lynch, Pierce, Fenner & Smith Incorporated, J.P. Morgan Securities Inc., and Morgan Stanley & Co. Incorporated.
  • 7The filing includes exhibits such as the underwriting agreement and legal opinions.

Frequently Asked Questions

This 8-K filing announces Vertex Pharmaceuticals' entry into a material definitive agreement concerning a significant public offering of its common stock. It details the number of shares offered, the price per share, and the underwriters involved.

Vertex Pharmaceuticals raised capital by selling a total of 13,000,000 shares. The initial sale was 11,500,000 shares at $38.50 per share, plus an additional 1,500,000 shares purchased by underwriters exercising their option at the same price. The total gross proceeds would be approximately $500.5 million (13,000,000 shares * $38.50/share).

This offering significantly increases the number of Vertex Pharmaceuticals' outstanding shares by 13,000,000. This dilutes the ownership percentage of existing shareholders and could impact earnings per share (EPS) unless the capital raised is effectively deployed to generate a commensurate increase in profits.

The offering was managed by a group of prominent underwriters, with Goldman, Sachs & Co. serving as the representative. Other key underwriters included Merrill Lynch, Pierce, Fenner & Smith Incorporated, J.P. Morgan Securities Inc., and Morgan Stanley & Co. Incorporated.